These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32047498)

  • 21. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system.
    Jin J; Joo KM; Nam Y; Kim DH; Lee SJ; Jo MY; Jin Y; Kim HS; Seo SW; Kim SJ; Nam DH; Kim WS
    Exp Ther Med; 2010 Nov; 1(6):943-946. PubMed ID: 22993623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
    Beum PV; Lindorfer MA; Taylor RP
    J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.
    Huang B; Abraham WD; Zheng Y; Bustamante López SC; Luo SS; Irvine DJ
    Sci Transl Med; 2015 Jun; 7(291):291ra94. PubMed ID: 26062846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
    Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
    J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
    Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
    J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts.
    Ghetie MA; Crank M; Kufert S; Pop I; Vitetta E
    J Immunother; 2006; 29(5):536-44. PubMed ID: 16971809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
    Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
    J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
    Juto A; Fink K; Al Nimer F; Piehl F
    Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and In Vivo Antitumor Efficacy in Combination with Rituximab.
    Kryza D; De Crozals G; Mathe D; Taleb Sidi-Boumedine J; Janier M; Chaix C; Dumontet C
    Bioconjug Chem; 2018 Mar; 29(3):804-812. PubMed ID: 29283559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancer.
    Borrajo E; Abellan-Pose R; Soto A; Garcia-Fuentes M; Csaba N; Alonso MJ; Vidal A
    J Control Release; 2016 Sep; 238():263-271. PubMed ID: 27476608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
    Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
    Beum PV; Kennedy AD; Taylor RP
    J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis of neuroborreliosis--lessons from a monkey model.
    Pachner AR; Schaefer H; Amemiya K; Cadavid D; Zhang WF; Reddy K; O'Neill T
    Wien Klin Wochenschr; 1998 Dec; 110(24):870-3. PubMed ID: 10048168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient Delivery of Nerve Growth Factors to the Central Nervous System for Neural Regeneration.
    Xu D; Wu D; Qin M; Nih LR; Liu C; Cao Z; Ren J; Chen X; He Z; Yu W; Guan J; Duan S; Liu F; Liu X; Li J; Harley D; Xu B; Hou L; Chen ISY; Wen J; Chen W; Pourtaheri S; Lu Y
    Adv Mater; 2019 Aug; 31(33):e1900727. PubMed ID: 31125138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-articular delivery of full-length antibodies through the use of an in situ forming depot.
    Fayd'herbe De Maudave A; Leconet W; Toupet K; Constantinides M; Bossis G; de Toledo M; Vialaret J; Hirtz C; Lopez-Noriega A; Jorgensen C; Noël D; Louis-Plence P; Grizot S; Villalba M
    J Control Release; 2022 Jan; 341():578-590. PubMed ID: 34915070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.